ClinicalTrials.gg
CompletedNCT06727838Updated Apr 24, 2026

Study on Drug Interaction of Metformin Tablets and HRS-7535 Tablets in Healthy Human

A Phase 1 interventional study of HRS-7535 tablets and Metformin Hydrochloride Extended-release Tablets in Diabetes, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Diabetes Mellitus by Jiangsu HengRui Medicine Co., Ltd. — 4 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
12th of 13
18 · median 30
Started
2024
with 1 other
Phase 1
13 of 13
4 open now
Registered
10th of 13
by date

Among the 13 studies in Diabetes Mellitus by Jiangsu HengRui Medicine Co., Ltd., this one is the 12th largest by enrollment, is one of 2 that started in 2024, is one of 13 in phase 1, and was the 10th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

4 of the 13 studies in Diabetes Mellitus by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Diabetes Mellitus by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This study was a single-center, open, fixed-sequence, self-controlled trial design conducted in healthy subjects.

03

Conditions studied

  • Diabetes

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign before the start of activities related to this experiment, be able to communicate well with the investigators, understand the procedures and methods of this experiment, and be willing to strictly follow the clinical trial protocol to complete this experiment;
  2. Healthy male aged 18-50 years old (including both ends of the value, subject to the signing of the informed consent);
  3. Weight ≥ 50 kg, and (BMI): 22\~26 kg/m2 (including both ends of the value);
  4. Signed informed consent to have no birth plan for 6 months after the last dose, and agreed to take effective measures.

Exclusion criteria

Exclusion Criteria:

  1. Have a history of drug or food allergy, or are allergic;
  2. Inability to swallow, chronic diarrhea and intestinal obstruction, or the presence of multiple other factors affecting the administration and absorption of drugs;
  3. > 450 ms was detected by 12-lead during screening or there were other abnormalities that were as determined by the investigator;
  4. surface antigen (HBsAg), virus (HCV) antibody, (HIV) antibody, syphilis antibody test positive;
  5. Those who smoked more than 5 cigarettes per day in the 3 months prior to screening and could not stop using any tobacco products during the test;
  6. Regular drinkers in the 6 months prior to screening, i.e. those who drink more than 14 units of alcohol per week (1 unit = 285 mL for beer, or 25 mL for spirits, or 100 mL for wine) and cannot stop using any alcohol-containing products during the test period, who test positive for alcohol breath test;
  7. Patients with a history of drug abuse, drug dependence (consultation) or positive urine drug abuse screening before drug administration;
  8. Patients who have received any surgery within 6 months before screening;
  9. Participants who have participated in clinical trials of any drug or medical device within 3 months prior to screening (subject to receiving experimental drugs or medical device intervention);
  10. Blood donation (or blood loss) and blood donation (or blood loss) ≥ 400 mL within 3 months before screening, or receiving blood transfusion;
  11. Patients who had any clinically significant acute disease within 1 month before screening;
  12. People who have taken any prescription, over-the-counter, Chinese herbal or health product within 14 days prior to taking the study drug, and plan to take any drug or health product other than the study drug during the trial;
  13. Patients with a history of severe hypoglycemia;
  14. People with a history of recurrent urinary tract infections, diabetes insipidus or/and genital fungal infections;
  15. Previous history of clinical gastric emptying abnormalities (such as gastric outlet obstruction), severe chronic gastrointestinal diseases (such as inflammatory bowel disease, active ulcers);
  16. Previous history or family history of medullary thyroid cancer, multiple endocrine adenomatosis type 2, previous history of pancreatitis or symptomatic gallbladder disease;
  17. 48h before the first dose until the end of the study, subjects refused to stop drinking or eating foods with high methylxanthine content, such as coffee, tea, cola, chocolate, etc.; For 7 days prior to the first dose until the end of the study, subjects refused to discontinue any beverage or food containing grapefruit; Those who have special dietary requirements and cannot comply with a unified diet;
  18. Physical examination, vital signs, laboratory examination, abdominal ultrasound, chest film and other abnormal and clinically significant examination results;
  19. Persons who have been vaccinated within 1 month prior to screening or plan to be vaccinated during the trial period;
  20. Subjects with other factors deemed unsuitable for participation in the study by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Treatment group

    Drug: HRS-7535 tablets · Drug: Metformin Hydrochloride Extended-release Tablets · Drug: Metformin Hydrochloride Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: 0 hour to 24 hours after the last dosing.

  2. Area under the plasma concentration-time curve from time zero to the time of last quantifiable analyte concentration (AUC0-t)

    Time frame: 0 hour to 24 hours after the last dosing.

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-∞)

    Time frame: 0 hour to 24 hours after the last dosing.

Secondary outcomes

  1. Time to reach maximum plasma concentration (Tmax)

    Time frame: 0 hour to 24 hours after the last dosing.

  2. Terminal half-life ( t1/2)

    Time frame: 0 hour to 24 hours after the last dosing.

  3. Apparent clearance (CL/F)

    Time frame: 0 hour to 24 hours after the last dosing.

  4. Apparent volume of distribution (Vz/F)

    Time frame: 0 hour to 24 hours after the last dosing.

  5. Incidence and severity of adverse events (AEs)

    Time frame: 0 hour to 24 hours after the last dosing.

07

Study locations

1 site
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221700, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Jan 2025, 0 months.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 0 months is below that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2024
First posted
Dec 11, 2024
StartActual
Dec 31, 2024
Primary completionActual
Jan 25, 2025
CompletionActual
Jan 25, 2025
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06727838
Responsible party
Sponsor
First posted
Dec 11, 2024
Start date
Dec 31, 2024
Primary completion
Jan 25, 2025
Completion
Jan 25, 2025
Last update
Apr 24, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-7535

Start the discussion